Results 281 to 290 of about 108,133 (341)

The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)

Expert Opinion on Drug Safety, 2023
Introduction Recently, the European Medicines Agency (EMA) received reports of suicidal thoughts and self-injury associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) liraglutide and semaglutide.
R. McIntyre, R. Mansur, J. Rosenblat, A. Kwan   +3 more
semanticscholar   +1 more source

Comparative effectiveness of glucagon‐like peptide‐1 receptor agonists for the management of obesity in adults without diabetes: A network meta‐analysis of randomized clinical trials

Obesity Reviews, 2022
Tirzepatide is a new glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) that has shown promising results for weight loss. A Bayesian network meta‐analysis was conducted to compare the efficacy and safety of GLP‐1RAs for obesity management.
Omar S. Alkhezi, Abdullah A. Alahmed, Osamah M. Alfayez, Osama A. Alzuman, Abdulaali R. Almutairi, O. Almohammed   +5 more
semanticscholar   +1 more source

Overview of Glucagon-like Peptide-1 Receptor Agonists

Home Healthcare Now, 2015
Type 2 diabetes mellitus is an increasingly prevalent disease in the United States and globally. Multiple pharmacologic therapies are typically required over time to achieve and maintain target blood glucose levels. When first-line oral medications such as metformin (Glucophage) are not effective in achieving desired glycosylated hemoglobin (HbA1C ...
Laura, Steadman, Joan S, Grant, Lucinda J, Graven   +2 more
openaire   +2 more sources

Glucagon-Like Peptide-1 Receptor Agonists

Incretin hormones are glucoregulatory neurohormones, and GLP-1 and GIP account for about 90% of the incretin effect.1 GLP-1 and GIP are secreted in response to food ingestion and act on the pancreas to stimulate glucose-dependent insulin secretion and blunt inappropriate glucagon secretion ...
Heather P. Whitley, Jennifer M. Trujillo
  +4 more sources

Renal protection with glucagon-like peptide-1 receptor agonists

Current Opinion in Pharmacology, 2020
There is an unmet need for renoprotective drugs for more pronounced reduction of albuminuria beyond that provided by renin-angiotensin system (RAS) blockers and for effective slowdown of eGFR decline independent of albuminuria. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have proven effective in reducing prespecified secondary composite ...
Vitale M., Haxhi J., Cirrito T., Pugliese G.   +3 more
openaire   +2 more sources

Glucagon-Like Peptide-1 Receptor Agonists—Use in Clinical Practice

Advances in Chronic Kidney Disease, 2021
In the past 2 decades, eight glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been approved for the management of type 2 diabetes, each with its peculiar molecular structure, pharmacokinetics, and metabolic effects. Along with their marked glucose-lowering actions, which occur both at fasting and in the postprandial phase without an increased ...
Tricò, Domenico, Solini, Anna
openaire   +3 more sources

Cardioprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists

Kardiologiia, 2014
In this paper we discuss pathogenetic mechanisms of cardiovascular risk reduction in patients with type 2 diabetes mellitus by glucagon-like peptide 1 (GLP-1) receptor agonists. Results of experimental studies and randomized clinical studies are presented, and perspectives for using GLP-1 agonists in patients with diabetic cardiovascular complications ...
A S, Ametov, L L, Kamynina, Z G, Akhmedova   +2 more
openaire   +2 more sources

Spending on Glucagon-Like Peptide-1 Receptor Agonists Among US Adults

JAMA Network Open
This economic evaluation estimates annual total US spending on glucagon-like peptide-1 receptor agonists from 2018 to 2023.
Stavros Tsipas, Tamkeen Khan, Fleetwood Loustalot, Klodiana Myftari, Gregory Wozniak   +4 more
semanticscholar   +1 more source

Obesity and Glucagon-Like Peptide-1 Receptor Agonists

JAMA
This Viewpoint discusses factors associated with the prevalence of obesity worldwide and whether the novel glucagon-like peptide-1 receptor agonists (GLP-1) can help unlock a health systems response to the obesity pandemic.
Francesca, Celletti, Francesco, Branca, Jeremy, Farrar   +2 more
openaire   +2 more sources

Glucagon-Like Peptide-1 Receptor Agonists: Beta-Cell Protection or Exhaustion?

Trends in Endocrinology & Metabolism, 2016
Glucagon-like peptide (GLP)-1 receptor agonists enhance insulin secretion and may improve pancreatic islet cell function. However, GLP-1 receptor (GLP-1R) agonist treatment may have more complex, and sometimes deleterious, effects on beta cells. We discuss the concepts of beta cell protection versus exhaustion for different GLP-1R agonists based on ...
van Raalte, Daniël H, Verchere, C Bruce
openaire   +4 more sources